Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Uranium Energy Corp (UEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs Uranium Energy Corp — how do they compare? Travere Therapeutics Inc. Common Stock trades at $54.94 (market cap $5.02B), while Uranium Energy Corp trades at $7.67 (market cap $3.82B). The key difference: Travere Therapeutics Inc. Common Stock is the larger of the two by market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Uranium Energy Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and Uranium Energy Corp for 38 Days on average.
| TVTX | UEC | |
|---|---|---|
Market Cap | $5.02B | $3.82B |
Volume | 2,060,842 | 13,882,337 |
Sector | Health | Energy |
52-Week High | $67.52 | $20.14 |
52-Week Low | $26.79 | $7.70 |
Typical Hold Time | 0 Days | 38 Days |
Enterprise Value | $5.15B | $3.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Uranium Energy (UEC) trades at $7.42, down 10.06% in the last 24 hours, amid a bearish technical signal despite bullish analyst consensus. The company reported a net loss of $87.66M on revenue of $66.84M in 2025, with negative margins and cash flow from operations. Recent news highlights expansion to two U.S. mines and a $93.13 per pound realized uranium price in fiscal 2026, though earnings misses in Q1 and Q2 2026 raise execution concerns.
The stock faces significant fundamental challenges with persistent losses and high cash burn, but Wall Street remains bullish with a $16.06 price target, betting on uranium demand growth. Key risks include unproven production sustainability and reliance on financing activities. Upside depends on successful operational scaling and favorable uranium market dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
